MX2022010201A - Uso de analogos de ciclosporina para el tratamiento de la fibrosis. - Google Patents
Uso de analogos de ciclosporina para el tratamiento de la fibrosis.Info
- Publication number
- MX2022010201A MX2022010201A MX2022010201A MX2022010201A MX2022010201A MX 2022010201 A MX2022010201 A MX 2022010201A MX 2022010201 A MX2022010201 A MX 2022010201A MX 2022010201 A MX2022010201 A MX 2022010201A MX 2022010201 A MX2022010201 A MX 2022010201A
- Authority
- MX
- Mexico
- Prior art keywords
- fibrosis
- treatment
- cyclosporine analogs
- crv431
- stereoisomer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
En el presente documento se divulgan métodos, composiciones y kits adecuados para su uso en la prevención, el tratamiento o la reversión de la fibrosis. Los métodos comprenden la administración a un sujeto que lo necesite de una composición que comprende un análogo de ciclosporina (por ejemplo, CRV431), o una sal, solvato y estereoisómero farmacéuticamente aceptable. Las composiciones y los kits comprenden un análogo de ciclosporina (por ejemplo, CRV431), o una sal, solvato, estereoisómero farmacéuticamente aceptable del mismo.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062978526P | 2020-02-19 | 2020-02-19 | |
| US202062981383P | 2020-02-25 | 2020-02-25 | |
| PCT/US2021/018639 WO2021168161A1 (en) | 2020-02-19 | 2021-02-19 | Use of cyclosporine analogues for treating fibrosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022010201A true MX2022010201A (es) | 2022-09-19 |
Family
ID=75108767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022010201A MX2022010201A (es) | 2020-02-19 | 2021-02-19 | Uso de analogos de ciclosporina para el tratamiento de la fibrosis. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US12409206B2 (es) |
| EP (1) | EP4106791A1 (es) |
| JP (2) | JP2023514837A (es) |
| KR (1) | KR20220143059A (es) |
| CN (1) | CN115427060A (es) |
| AU (1) | AU2021224676A1 (es) |
| BR (1) | BR112022016522A2 (es) |
| CA (1) | CA3171882A1 (es) |
| IL (1) | IL295452A (es) |
| MX (1) | MX2022010201A (es) |
| PH (1) | PH12022552089A1 (es) |
| TW (1) | TW202143994A (es) |
| WO (1) | WO2021168161A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120437063A (zh) * | 2025-05-13 | 2025-08-08 | 上海交通大学医学院附属第九人民医院 | 靶向肺巨噬细胞的脂质体及其在肺纤维化治疗中的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5372807A (en) | 1990-05-14 | 1994-12-13 | University Of Medicine And Dentistry Of New Jersey | Polymers containing antifibrotic agents, compositions containing such polymers, and methods of preparation and use |
| US20020006901A1 (en) * | 1999-02-05 | 2002-01-17 | Aldo T. Iacono | Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease |
| ES2700141T3 (es) | 2007-08-02 | 2019-02-14 | Gilead Biologics Inc | Anticuerpos inhibidores LOXL2 y usos de los mismos |
| US8709731B2 (en) | 2007-08-24 | 2014-04-29 | Oncotherapy Science, Inc. | DKK1 oncogene as therapeutic target for cancer and a diagnosing marker |
| EP2409154B1 (en) * | 2009-03-19 | 2017-08-02 | Universite D'angers | Non-invasive method for assessing liver fibrosis progression |
| WO2011081214A1 (ja) | 2009-12-28 | 2011-07-07 | 国立大学法人東京大学 | オートタキシン測定による肝線維化の検査方法および検査薬 |
| JP6144627B2 (ja) | 2010-12-15 | 2017-06-07 | コントラヴィア ファーマシューティカルズ、インク． | アミノ酸１および３で修飾されたシクロスポリン類似体分子 |
| WO2017015720A1 (en) | 2015-07-30 | 2017-02-02 | Monash University | Fibrotic treatment |
| WO2018106928A1 (en) | 2016-12-08 | 2018-06-14 | Contravir Pharmaceuticals, Inc. | Treatment and prevention of hbv diseases by cyclosporine analogue molecules modified at amino acides 1 and 3 |
| AR111464A1 (es) | 2017-04-14 | 2019-07-17 | Contravir Pharmaceuticals Inc | Terapia combinada para el tratamiento de infecciones virales |
| SMT202300139T1 (it) | 2018-11-26 | 2023-07-20 | Hepion Pharmaceuticals Inc | Formulazioni farmaceutiche di analoghi della ciclosporina |
| AU2021227230A1 (en) * | 2020-02-25 | 2022-09-08 | Hepion Pharmaceuticals, Inc. | Use of cyclosporine analogues for treating cancer |
-
2021
- 2021-02-19 CN CN202180029303.4A patent/CN115427060A/zh active Pending
- 2021-02-19 TW TW110105739A patent/TW202143994A/zh unknown
- 2021-02-19 WO PCT/US2021/018639 patent/WO2021168161A1/en not_active Ceased
- 2021-02-19 AU AU2021224676A patent/AU2021224676A1/en active Pending
- 2021-02-19 MX MX2022010201A patent/MX2022010201A/es unknown
- 2021-02-19 CA CA3171882A patent/CA3171882A1/en active Pending
- 2021-02-19 EP EP21713171.3A patent/EP4106791A1/en active Pending
- 2021-02-19 BR BR112022016522A patent/BR112022016522A2/pt unknown
- 2021-02-19 US US17/179,406 patent/US12409206B2/en active Active
- 2021-02-19 JP JP2022549839A patent/JP2023514837A/ja active Pending
- 2021-02-19 KR KR1020227031378A patent/KR20220143059A/ko active Pending
- 2021-02-19 IL IL295452A patent/IL295452A/en unknown
- 2021-02-19 PH PH1/2022/552089A patent/PH12022552089A1/en unknown
-
2025
- 2025-08-06 US US19/292,368 patent/US20250360181A1/en active Pending
- 2025-12-22 JP JP2025272755A patent/JP2026069500A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023514837A (ja) | 2023-04-11 |
| WO2021168161A1 (en) | 2021-08-26 |
| JP2026069500A (ja) | 2026-04-23 |
| TW202143994A (zh) | 2021-12-01 |
| US12409206B2 (en) | 2025-09-09 |
| EP4106791A1 (en) | 2022-12-28 |
| PH12022552089A1 (en) | 2023-11-20 |
| CN115427060A (zh) | 2022-12-02 |
| CA3171882A1 (en) | 2021-08-26 |
| AU2021224676A1 (en) | 2022-09-08 |
| US20250360181A1 (en) | 2025-11-27 |
| BR112022016522A2 (pt) | 2022-10-11 |
| KR20220143059A (ko) | 2022-10-24 |
| US20210260153A1 (en) | 2021-08-26 |
| IL295452A (en) | 2022-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019003542A1 (es) | Métodos de tratamiento para la fibrosis quística. | |
| CO2023013050A2 (es) | Composiciones de psilocibina, métodos para prepararlas y métodos de uso de estas | |
| ECSP22018571A (es) | Degradadores bifuncionales de brd9 y sus métodos de uso | |
| CO2021010490A2 (es) | Compuestos, composiciones y métodos | |
| CO2022017622A2 (es) | Inhibidores de quinasa nek7 | |
| AR107871A1 (es) | Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos | |
| MX2020002191A (es) | Agentes antivirales contra la hepatitis b. | |
| MX2024008886A (es) | Sulfonamida sustituida con trifluorometilo como inhibidor selectivo de bcl-2. | |
| DOP2025000146A (es) | Compuesto quimérico protac, método de preparación del mismo y uso del mismo | |
| AR132698A1 (es) | DERIVADOS ESPIRO COMO INHIBIDORES DE LA HELICASA TIPO RecQ DEL SÍNDROME DE WERNER (WRN) | |
| CL2021001629A1 (es) | Compuestos de halo-alilamina y uso de los mismos | |
| MX2024002581A (es) | Lou064 para el tratamiento de la esclerosis multiple. | |
| MX2022001429A (es) | Formulaciones que incluyen dihidrohonokiol. | |
| CL2025000581A1 (es) | Estructuras derivadas de tn3 específicas de cd40l; tratamiento, prevención del síndrome de sjögren | |
| CO2020013427A2 (es) | Formulaciones de ciclosporina para uso en el tratamiento del síndrome de bronquiolitis obliterante (bos) | |
| AR121404A1 (es) | Uso de análogos de ciclosporina para tratar cáncer | |
| AR115883A1 (es) | Composición farmacéutica para el tratamiento de la adicción a sustancias psicoactivas y/o para la prevención de las recaídas a dicha adicción | |
| CL2025001901A1 (es) | Uso de pridopidina para el tratamiento de la enfermedad de huntington juvenil. | |
| MX2025002228A (es) | Metodos para el tratamiento o la profilaxis de la endometriosis | |
| AR121376A1 (es) | Uso de análogos de ciclosporina para tratar la fibrosis | |
| PH12022552089A1 (en) | Use of cyclosporine analogues for treating fibrosis | |
| DOP2021000028A (es) | Formulaciones de dendrímeros | |
| AR105378A1 (es) | Métodos de tratamiento de trastornos del desarrollo con gaboxadol | |
| CO2021010512A2 (es) | Compuesto heterociclo pentacíclico | |
| MX2024014869A (es) | Composicion oftalmica de rifamicina y uso de la misma |